2-Trifluoromethyl-5-Nitrobenzonitrile | CAS:887350-95-0

We serve 2-Trifluoromethyl-5-Nitrobenzonitrile CAS:887350-95-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Trifluoromethyl-5-Nitrobenzonitrile

Chemical Name:2-Trifluoromethyl-5-Nitrobenzonitrile
CAS.NO:887350-95-0
Synonyms:2-Trifluoromethyl-5-Nitrobenzonitrile
5-Nitro-2-(trifluoromethyl)benzonitrile
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 282.4±40.0 °C at 760 mmHg
Molecular Formula C8H3F3N2O2
Molecular Weight 216.117
Flash Point 124.6±27.3 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.499
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Trifluoromethyl-5-Nitrobenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Nitro-2-(trifluoromethyl)benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Nitro-2-(trifluoromethyl)benzonitrile Use and application,5-Nitro-2-(trifluoromethyl)benzonitrile technical grade,usp/ep/jp grade.


Related News: The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.trans-4-Cyclohexyl-L-proline manufacturer To date, eight cases have been confirmed in the US: three people in California, two in Illinois and one individual each in Massachusetts, Washington State, and Arizona.5-Fluoro-2-iodotoluene supplier As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.2-Amino-5-bromopyridine vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.